Drug-induced Liver Injury Clinical Trial
— DILI-PMOfficial title:
A Prognostic Model for Drug-induced Liver Injury in China : A Multi-center, Prospective Cohort Study
A prospective, multi-center, non-interventional cohort study is going to conduct to explore the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of Drug-induced liver injury (DILI) in China and screen novel serum markers. A prognostic model incorporating with the novel serum marker(s) for DILI would be established and validated to imporve the prognosis of patients in China .
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. RUCAM =6 and met one of the following biochemical conditions: (1) ALT=5 ULN, (2) or ALP =2 ULN, (3) or ALT=3 ULN and TBil=2 ULN. 2. RUCAM between 3-5, five experienced hepatologists in leading site evaluate and vote the diagnosis of DILI, the case would be enrolled if only =4 out of 5 hepatologists agree with the diagnosis. 3. Onset to enrollment =3 months. Exclusion Criteria: 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male >40g/d, female >20g/d, and =5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Autoimmune hepatitis: International Autoimmune Hepatitis Group (IAHG) simplified score =6 or complicated score =10, or differentiation from autoimmune hepatitis is impossible during enrollment. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Friendship Hospital, Capital Medical University | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Friendship Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | death/liver transplantation | DILI has a primary, contributory role for the death (liver-related mortality) or no role for the death (all-cause mortality) .
DILI is the primary indication for liver transplantation. |
1 year | |
Primary | acute liver failure | Acute liver failure is defined as elevated bilirubin and prolonged international normalized ratio (INR) =1.5 accompanied by mental disturbance within 26 weeks after DILI onset without underlying chronic liver diseases. | 1 year | |
Secondary | chronic DILI | Chronicity is defined as the presence of any one of the following: (i) persistently elevated liver biochemistry indexes; (ii) radiological or histological evidence of persistent liver injury at one year after DILI onset. | 2 years | |
Secondary | recovery | Recovery status is defined as clinical and biochemical resolution within 1 year after DILI onset, with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =40 U/L, alkaline phosphatase (ALP) =150 U/L, and total bilirubin (TB) =1.5 upper limits of normal (ULN) (25.65 µmol/L). | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Completed |
NCT03092817 -
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
|
Phase 3 | |
Completed |
NCT03211208 -
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
|
||
Not yet recruiting |
NCT02061826 -
Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)
|
N/A | |
Completed |
NCT02182167 -
A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis
|
Phase 2/Phase 3 | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A | |
Not yet recruiting |
NCT03091218 -
Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.
|
N/A | |
Not yet recruiting |
NCT03091244 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.
|
N/A | |
Not yet recruiting |
NCT03091556 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.
|
N/A | |
Not yet recruiting |
NCT03060252 -
Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill
|
N/A | |
Not yet recruiting |
NCT03091608 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule
|
N/A | |
Completed |
NCT02407964 -
A Retrospective Study on Drug Induced Liver Injury in China
|
N/A | |
Active, not recruiting |
NCT05144217 -
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
|
Phase 2/Phase 3 | |
Completed |
NCT01705041 -
Preliminary Evaluation of a Point-Of-Care Liver Function Test
|
N/A | |
Recruiting |
NCT02086708 -
Ultrasound Method to Measure Fibrosis of the Liver in Children
|
N/A | |
Recruiting |
NCT05465642 -
Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
|
||
Completed |
NCT01434173 -
Risk of Acute Liver Injury in Users of Antimicrobials
|
N/A | |
Completed |
NCT05532345 -
Discrimination of DILI and AIH by Artificial Intelligence
|
||
Completed |
NCT03602703 -
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
|
||
Active, not recruiting |
NCT03100786 -
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
|
Phase 3 |